nach oben

American Journal of Clinical Dermatology

Erschienen in:

15.09.2023 | Review Article

Oral Lichen Planus: An Update on Diagnosis and Management

verfasst von: Agathe Louisy, Eiryann Humbert, Mahtab Samimi

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Oral lichen planus (OLP) is a chronic inflammatory disease whose pathogenesis involves a T-cell mediated, epithelium-directed inflammation in response to unknown antigen(s). The disease evolves by intermittent flares and displays polymorphous clinical features (reticular, erosive, atrophic, plaque, papular, bullous, etc.). When present, symptoms vary depending on the clinical form and range from discomfort to severe pain. Topical superpotent corticosteroids constitute the first-line treatment of symptomatic flares, whereas a wide range of second/third-line treatments are available among topical calcineurin inhibitors, systemic corticosteroids, systemic retinoids, topical/systemic immunomodulators, etc. Follow-up of patients is necessary to detect transformation into squamous cell carcinoma, occurring in approximately 1% of patients.

González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, González-Ruiz L, Ayén Á, Lenouvel D, et al. Worldwide prevalence of oral lichen planus: a systematic review and meta-analysis. Oral Dis. 2021;27(4):813–28.PubMedCrossRef

Cassol-Spanemberg J, Rodríguez-de Rivera-Campillo ME, Otero-Rey EM, Estrugo-Devesa A, Jané-Salas E, López-López J. Oral lichen planus and its relationship with systemic diseases. A review of evidence. J Clin Exp Dent. 2018;10(9):e938–44.PubMedPubMedCentral

Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46(2):207–14.PubMedCrossRef

Shikha, Gupta S, Mahajan A, Ambika, Garg R, Ghosh S. Childhood oral lichen planus: a case series with review of literature. Eur Arch Paediatr Dent. 2022;23(2):341–53.

Kurago ZB. Etiology and pathogenesis of oral lichen planus: an overview. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):72–80.PubMedCrossRef

El-Howati A, Thornhill MH, Colley HE, Murdoch C. Immune mechanisms in oral lichen planus. Oral Dis. 2023;29(4):1400–15.PubMedCrossRef

Baek K, Lee J, Lee A, Lee J, Yoon HJ, Park HK, et al. Characterization of intratissue bacterial communities and isolation of Escherichia coli from oral lichen planus lesions. Sci Rep. 2020;10(1):3495.PubMedPubMedCentralCrossRef

Villa TG, Sánchez-Pérez Á, Sieiro C. Oral lichen planus: a microbiologist point of view. Int Microbiol Off J Span Soc Microbiol. 2021;24(3):275–89.

Wang H, Zhang D, Han Q, Zhao X, Zeng X, Xu Y, et al. Role of distinct CD4(+) T helper subset in pathogenesis of oral lichen planus. J Oral Pathol Med. 2016;45(6):385–93.PubMedCrossRef

10.

Shan J, Li S, Wang C, Liu L, Wang X, Zhu D, et al. Expression and biological functions of the CCL5-CCR5 axis in oral lichen planus. Exp Dermatol. 2019;28(7):816–21.PubMedCrossRef

11.

Piccinni MP, Lombardelli L, Logiodice F, Tesi D, Kullolli O, Biagiotti R, et al. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus. Oral Dis. 2014;20(2):212–8.PubMedCrossRef

12.

Lodi G, Giuliani M, Majorana A, Sardella A, Bez C, Demarosi F, et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol. 2004;151(6):1172–81.PubMedCrossRef

13.

Lodi G, Pellicano R, Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis. 2010;16(7):601–12.PubMedCrossRef

14.

Petti S, Rabiei M, De Luca M, Scully C. The magnitude of the association between hepatitis C virus infection and oral lichen planus: meta-analysis and case control study. Odontology. 2011;99(2):168–78.PubMedCrossRef

15.

Alaizari NA, Al-Maweri SA, Al-Shamiri HM, Tarakji B, Shugaa-Addin B. Hepatitis C virus infections in oral lichen planus: a systematic review and meta-analysis. Aust Dent J. 2016;61(3):282–7.PubMedCrossRef

16.

Carrozzo M, Quadri R, Latorre P, Pentenero M, Paganin S, Bertolusso G, et al. Molecular evidence that the hepatitis C virus replicates in the oral mucosa. J Hepatol. 2002;37(3):364–9.PubMedCrossRef

17.

Pilli M, Penna A, Zerbini A, Vescovi P, Manfredi M, Negro F, et al. Hepatology. 2002;36(6):1446–52.PubMedCrossRef

18.

González-Moles MÁ, de Porras-Carrique T, Ramos-García P. Association of oral lichen planus with hepatic disorders and hepatocellular carcinoma: systematic review and meta-analysis. Med Oral Patol Oral Cirugia Bucal. 2023;18:25661.

19.

Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis. 2011;17(Suppl 1):58–72.PubMedCrossRef

20.

Ma J, Zhang J, Zhang Y, Lv T, Liu J. The magnitude of the association between human papillomavirus and oral lichen planus: a meta-analysis. PLoS ONE. 2016;11(8): e0161339.PubMedPubMedCentralCrossRef

21.

Viguier M, Bachelez H, Poirier B, Kagan J, Battistella M, Aubin F, et al. Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus. J Invest Dermatol. 2015;135(2):418–24.PubMedCrossRef

22.

Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 1978;46(4):518–39.PubMedCrossRef

23.

van der Meij EH, Schepman KP, Plonait DR, Axéll T, van der Waal I. Interobserver and intraobserver variability in the clinical assessment of oral lichen planus. J Oral Pathol Med. 2002;31(2):95–8.PubMedCrossRef

24.

van der Meij EH, van der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med. 2003;32(9):507–12.PubMedCrossRef

25.

Cheng YSL, Gould A, Kurago Z, Fantasia J, Muller S. Diagnosis of oral lichen planus: a position paper of the American Academy of Oral and Maxillofacial Pathology. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(3):332–54.PubMedCrossRef

26.

González-Moles MÁ, Ramos-García P. Oral lichen planus and related lesions. What should we accept based on the available evidence? Oral Dis. 2022.

27.

González-Moles MÁ, Ramos-García P, Warnakulasuriya S. An appraisal of highest quality studies reporting malignant transformation of oral lichen planus based on a systematic review. Oral Dis. 2021;27(8):1908–18.PubMedCrossRef

28.

González-Moles MÁ, Ruiz-Ávila I, González-Ruiz L, Ayén Á, Gil-Montoya JA, Ramos-García P. Malignant transformation risk of oral lichen planus: A systematic review and comprehensive meta-analysis. Oral Oncol. 2019;96:121–30.PubMedCrossRef

29.

Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(Suppl):S25.e1-12.PubMed

30.

Campana F, Lan R, Girard C, Rochefort J, Le Pelletier F, Leroux-Villet C, et al. French guidelines for the management of oral lichen planus (excluding pharmacological therapy). Ann Dermatol Venereol. 2022;149(1):14–27.PubMedCrossRef

31.

Fortuna G, Aria M, Schiavo JH. Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review. Eur J Clin Pharmacol. 2017;73(12):1523–37.PubMedCrossRef

32.

Ramos-García P, González-Moles MÁ, Warnakulasuriya S. Oral cancer development in lichen planus and related conditions-3.0 evidence level: A systematic review of systematic reviews. Oral Dis. 2021 Nov;27(8):1919–35.

33.

Alrashdan MS, Cirillo N, McCullough M. Oral lichen planus: a literature review and update. Arch Dermatol Res. 2016;308(8):539–51.PubMedCrossRef

34.

Dunsche A, Kästel I, Terheyden H, Springer ING, Christophers E, Brasch J. Oral lichenoid reactions associated with amalgam: improvement after amalgam removal. Br J Dermatol. 2003;148(1):70–6.PubMedCrossRef

35.

Thornhill MH, Pemberton MN, Simmons RK, Theaker ED. Amalgam-contact hypersensitivity lesions and oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(3):291–9.PubMedCrossRef

36.

López-Jornet P, Camacho-Alonso F. Do metal restorations in mouth alter clinical and histological appearance of oral lichen planus? N Y State Dent J. 2008;74(6):40–3.PubMed

37.

Cobos-Fuentes MJ, Martínez-Sahuquillo-Márquez A, Gallardo-Castillo I, Armas-Padrón JR, Moreno-Fernández A, Bullón-Fernández P. Oral lichenoid lesions related to contact with dental materials: a literature review. Med Oral Patol Oral Cirugia Bucal. 2009;14(10):e514-520.CrossRef

38.

Issa Y, Brunton PA, Glenny AM, Duxbury AJ. Healing of oral lichenoid lesions after replacing amalgam restorations: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98(5):553–65.PubMedCrossRef

39.

Ibrahim SS, Ragy NI, Nagy NA, El-kammar H, Elbakry AM, Ezzatt OM. Evaluation of muco-adhesive tacrolimus patch on caspase-3 induced apoptosis in oral lichen planus: a randomized clinical trial. BMC Oral Health. 2023;14(23):99.CrossRef

40.

Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Womens Dermatol. 2015;1(3):140–9.PubMedPubMedCentralCrossRef

41.

Gorouhi F, Davari P, Fazel N. Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. ScientificWorldJournal. 2014;2014: 742826.PubMedPubMedCentralCrossRef

42.

Eisen D. The evaluation of cutaneous, genital, scalp, nail, esophageal, and ocular involvement in patients with oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(4):431–6.PubMedCrossRef

43.

Hewitt J, Pelisse M, Lessana-Leibowitch M, Sedel D, Fischesser D, Moyal-Barracco M, et al. Vulvovaginogingival syndrome. New characteristic grouping of plurimucous erosive lichen planus. Rev Stomatol Chir Maxillofac. 1985;86(2):57–65.PubMed

44.

Setterfield JF, Neill S, Shirlaw PJ, Theron J, Vaughan R, Escudier M, et al. The vulvovaginal gingival syndrome: a severe subgroup of lichen planus with characteristic clinical features and a novel association with the class II HLA DQB1*0201 allele. J Am Acad Dermatol. 2006;55(1):98–113.PubMedCrossRef

45.

Gupta MK, Lipner SR. Review of nail lichen planus: epidemiology, pathogenesis, diagnosis, and treatment. Dermatol Clin. 2021;39(2):221–30.PubMedCrossRef

46.

Schauer F, Monasterio C, Technau-Hafsi K, Kern JS, Lazaro A, Deibert P, et al. Esophageal lichen planus: towards diagnosis of an underdiagnosed disease. Scand J Gastroenterol. 2019;54(10):1189–98.PubMedCrossRef

47.

Decker A, Schauer F, Lazaro A, Monasterio C, Schmidt AR, Schmitt-Graeff A, et al. Esophageal lichen planus: current knowledge, challenges and future perspectives. World J Gastroenterol. 2022;28(41):5893–909.PubMedPubMedCentralCrossRef

48.

Rennie CE, Dwivedi RC, Khan AS, Agrawal N, Ziyada W. Lichen planus of the larynx. J Laryngol Otol. 2011;125(4):432–5.PubMedCrossRef

49.

Shaikh ZI, Arfan-ul-Bari, Mashhood AA, Qayyum A, Latif-ur-Rahman. Mucosal lichen planus simultaneously involving oral mucosa, conjunctiva and larynx. J Coll Physicians Surg Pak JCPSP. 2010;20(7):478–9.

50.

Sharma N, Malhotra SK, Kuthial M, Chahal KS. Vulvo-vaginal ano-gingival syndrome: Another variant of mucosal lichen planus. Indian J Sex Transm Dis AIDS. 2017;38(1):86–8.PubMedPubMedCentralCrossRef

51.

Thorne JE, Jabs DA, Nikolskaia OV, Mimouni D, Anhalt GJ, Nousari HC. Lichen planus and cicatrizing conjunctivitis: characterization of five cases. Am J Ophthalmol. 2003;136(2):239–43.PubMedCrossRef

52.

Mohebbi M, Mirghorbani M, Banafshe Afshan A, Towfighi M. Lichen planus in ocular surface: major presentations and treatments. Ocul Immunol Inflamm. 2019;27(6):987–94.PubMedCrossRef

53.

González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, Ayén Á, González-Ruiz L, Ruiz-Ávila I, et al. Dysplasia in oral lichen planus: relevance, controversies and challenges. A position paper. Med Oral Patol Oral Cirugia Bucal. 2021;26(4):e541–8.CrossRef

54.

Abe A, Ito Y, Hayashi H, Momokita M, Taniguchi S, Nakayama A. Evaluation of the classification and clinical characteristics of oral lichen planus and its treatment effect in different clinical types: a retrospective study. Adv Oral Maxillofac Surg. 2022;1(8): 100369.CrossRef

55.

Hiremath S, Kale AD, Hallikerimath S. Clinico-pathological study to evaluate oral lichen planus for the establishment of clinical and histopathological diagnostic criteria. Turk Patoloji Derg. 2015;31(1):24–9.PubMed

56.

Mravak-Stipetić M, Lončar-Brzak B, Bakale-Hodak I, Sabol I, Seiwerth S, Majstorović M, et al. Clinicopathologic correlation of oral lichen planus and oral lichenoid lesions: a preliminary study. ScientificWorldJournal. 2014;2014: 746874.PubMedPubMedCentralCrossRef

57.

Solomon LW, Helm TN, Stevens C, Neiders ME, Kumar V. Clinical and immunopathologic findings in oral lichen planus pemphigoides. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(6):808–13.PubMedCrossRef

58.

Hübner F, Langan EA, Recke A. Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering. Front Immunol. 2019;10:1389.PubMedPubMedCentralCrossRef

59.

Azzi L, Cerati M, Lombardo M, Pellilli M, Croveri F, Maurino V, et al. Chronic ulcerative stomatitis: a comprehensive review and proposal for diagnostic criteria. Oral Dis. 2019;25(6):1465–91.PubMedCrossRef

60.

Halonen M, Siponen M. Lichenoid lesions of the upper labial mucosa: a systematic review and a report of a new case with extensive follow-up. Acta Odontol Scand. 2023;81(1):29–39.PubMedCrossRef

61.

Ramos-e-Silva M, de-Moura-Castro Jacques C, Coelho da Silva Carneiro S. Premalignant nature of oral and vulval lichen planus: facts and controversies. Clin Dermatol. 2010;28(5):563–7.

62.

Lodi G, Manfredi M, Mercadante V, Murphy R, Carrozzo M. Interventions for treating oral lichen planus: corticosteroid therapies. Cochrane Database Syst Rev. 2020;2(2):CD001168.

63.

Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36(10):575–80.PubMedCrossRef

64.

Aghbari SMH, Abushouk AI, Attia A, Elmaraezy A, Menshawy A, Ahmed MS, et al. Malignant transformation of oral lichen planus and oral lichenoid lesions: a meta-analysis of 20095 patient data. Oral Oncol. 2017;68:92–102.PubMedCrossRef

65.

González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, González-Ruiz L, Ayén Á, Lenouvel D, et al. Clinicopathological and prognostic characteristics of oral squamous cell carcinomas arising in patients with oral lichen planus: a systematic review and a comprehensive meta-analysis. Oral Oncol. 2020;106: 104688.PubMedCrossRef

66.

Bombeccari GP, Guzzi G, Tettamanti M, Giannì AB, Baj A, Pallotti F, et al. Oral lichen planus and malignant transformation: a longitudinal cohort study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(3):328–34.PubMedCrossRef

67.

Gandolfo S, Richiardi L, Carrozzo M, Broccoletti R, Carbone M, Pagano M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol. 2004;40(1):77–83.PubMedCrossRef

68.

Carbone M, Arduino PG, Carrozzo M, Gandolfo S, Argiolas MR, Bertolusso G, et al. Course of oral lichen planus: a retrospective study of 808 northern Italian patients. Oral Dis. 2009;15(3):235–43.PubMedCrossRef

69.

Ioannides D, Vakirlis E, Kemeny L, Marinovic B, Massone C, Murphy R, et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2020;34(7):1403–14.PubMedCrossRef

70.

Liu C, Xie B, Yang Y, Lin D, Wang C, Lin M, et al. Efficacy of intralesional betamethasone for erosive oral lichen planus and evaluation of recurrence: a randomized, controlled trial. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(5):584–90.PubMedCrossRef

71.

Savage NW, McCullough MJ. Topical corticosteroids in dental practice. Aust Dent J. 2005;50(4 Suppl 2):S40-44.PubMed

72.

da Silva EL, de Lima TB, Rados PV, Visioli F. Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis. Clin Oral Investig. 2021;25(9):5149–69.PubMedCrossRef

73.

Samycia M, Lin AN. Efficacy of topical calcineurin inhibitors in lichen planus. J Cutan Med Surg. 2012;16(4):221–9.PubMedCrossRef

74.

Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83(2):375–81.PubMedCrossRef

75.

Ju HJ, Han JH, Kim MS, Lee SH, Shin JW, Choi M, et al. The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo. J Am Acad Dermatol. 2021;84(6):1619–27.PubMedCrossRef

76.

Weiner DM, Clark AK, Bhansali RS, Pappas-Taffer L, Barta SK, Villasenor-Park J, et al. Usage and safety of topical tacrolimus in patients with mycosis fungoides. Clin Exp Dermatol. 2022;47(6):1200–1.PubMedCrossRef

77.

Arana A, Pottegård A, Kuiper JG, Booth H, Reutfors J, Calingaert B, et al. Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clin Epidemiol. 2021;13:1141–53.PubMedPubMedCentralCrossRef

78.

Thongprasom K, Chaimusig M, Korkij W, Sererat T, Luangjarmekorn L, Rojwattanasirivej S. A randomized-controlled trial to compare topical cyclosporin with triamcinolone acetonide for the treatment of oral lichen planus. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2007;36(3):142–6.

79.

Scardina GA, Messina P, Carini F, Maresi E. A randomized trial assessing the effectiveness of different concentrations of isotretinoin in the management of lichen planus. Int J Oral Maxillofac Surg. 2006;35(1):67–71.PubMedCrossRef

80.

Singh AR, Rai A, Aftab M, Jain S, Singh M. Efficacy of steroidal vs non-steroidal agents in oral lichen planus: a randomised, open-label study. J Laryngol Otol. 2017;131(1):69–76.PubMedCrossRef

81.

Petruzzi M, Lucchese A, Lajolo C, Campus G, Lauritano D, Serpico R. Topical retinoids in oral lichen planus treatment: an overview. Dermatol Basel Switz. 2013;226(1):61–7.CrossRef

82.

Samimi M, Le Gouge A, Boralevi F, Passeron T, Pascal F, Bernard P, et al. Topical rapamycin versus betamethasone dipropionate ointment for treating oral erosive lichen planus: a randomized, double-blind, controlled study. J Eur Acad Dermatol Venereol. 2020;34(10):2384–91.PubMedCrossRef

83.

Ali S, Wahbi W. The efficacy of aloe vera in management of oral lichen planus: a systematic review and meta-analysis. Oral Dis. 2017;23(7):913–8.PubMedCrossRef

84.

Carbone M, Goss E, Carrozzo M, Castellano S, Conrotto D, Broccoletti R, et al. Systemic and topical corticosteroid treatment of oral lichen planus: a comparative study with long-term follow-up. J Oral Pathol Med. 2003;32(6):323–9.PubMedCrossRef

85.

Gupta S, Ghosh S, Gupta S. Interventions for the management of oral lichen planus: a review of the conventional and novel therapies. Oral Dis. 2017;23(8):1029–42.PubMedCrossRef

86.

Torti DC, Jorizzo JL, McCarty MA. Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol. 2007;143(4):511–5.PubMedCrossRef

87.

Handler HL. Isotretinoin for oral lichen planus. J Am Acad Dermatol. 1984;10(4):674.PubMedCrossRef

88.

Alsenaid A, Alamri A, Ruzicka T, Wolf R. Effective and safe use of alitretinoin after acitretin failure in oral lichen planus. Dermatol Ther. 2020;33(6): e14441.PubMedCrossRef

89.

Kunz M, Urosevic-Maiwald M, Goldinger SM, Frauchiger AL, Dreier J, Belloni B, et al. Efficacy and safety of oral alitretinoin in severe oral lichen planus—results of a prospective pilot study. J Eur Acad Dermatol Venereol. 2016;30(2):293–8.PubMedCrossRef

90.

Kolios AGA, Marques Maggio E, Gubler C, Cozzio A, Dummer R, French LE, et al. Oral, esophageal and cutaneous lichen ruber planus controlled with alitretinoin: case report and review of the literature. Dermatol Basel Switz. 2013;226(4):302–10.CrossRef

91.

Rivas-Tolosa N, Requena C, Llombart B, Alcalá R, Serra-Guillén C, Calomarde L, et al. Antimalarial drugs for the treatment of oral erosive lichen planus. Dermatol Basel Switz. 2016;232(1):86–90.CrossRef

92.

Eisen D. Hydroxychloroquine sulfate (plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol. 1993;28(4):609–12.PubMedCrossRef

93.

Raj SC, Baral D, Garhnayak L, Mahapatra A, Patnaik K, Tabassum S, et al. Hydroxychloroquine—a new treatment option for erosive oral lichen planus. Indian J Dent Res Off Publ Indian Soc Dent Res. 2021;32(2):192–8.CrossRef

94.

Yeshurun A, Bergman R, Bathish N, Khamaysi Z. Hydroxychloroquine sulphate therapy of erosive oral lichen planus. Australas J Dermatol. 2019;60(2):e109–12.PubMedCrossRef

95.

Turan H, Baskan EB, Tunali S, Yazici S, Saricaoglu H. Methotrexate for the treatment of generalized lichen planus. J Am Acad Dermatol. 2009;60(1):164–6.PubMedCrossRef

96.

Lajevardi V, Ghodsi SZ, Hallaji Z, Shafiei Z, Aghazadeh N, Akbari Z. Treatment of erosive oral lichen planus with methotrexate. J Dtsch Dermatol Ges. 2016;14(3):286–93.PubMed

97.

Verma KK, Mittal R, Manchanda Y. Azathioprine for the treatment of severe erosive oral and generalized lichen planus. Acta Derm Venereol. 2001;81(5):378–9.PubMedCrossRef

98.

Wee JS, Shirlaw PJ, Challacombe SJ, Setterfield JF. Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients. Br J Dermatol. 2012;167(1):36–43.PubMedCrossRef

99.

Macario-Barrel A, Balguerie X, Joly P. Treatment of erosive oral lichen planus with thalidomide. Ann Dermatol Venereol. 2003;130(12 Pt 1):1109–12.PubMed

100.

Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalidomide. Arch Dermatol. 2000;136(12):1442–3.PubMedCrossRef

101.

Chainani-Wu N, Collins K, Silverman S. Use of curcuminoids in a cohort of patients with oral lichen planus, an autoimmune disease. Phytomedicine. 2012;19(5):418–23.PubMedCrossRef

102.

Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol. 2012;66(5):752–60.PubMedCrossRef

103.

White CM, Chamberlin K, Eisenberg E. Curcumin, a turmeric extract, for oral lichen planus: A systematic review. Oral Dis. 2019;25(3):720–5.PubMedCrossRef

104.

Yarom N. Etanercept for the management of oral lichen planus. Am J Clin Dermatol. 2007;8(2):121–121.PubMedCrossRef

105.

Chao TJ. Adalimumab in the management of cutaneous and oral lichen planus. Cutis. 2009;84(6):325–8.PubMed

106.

Holló P, Szakonyi J, Kiss D, Jokai H, Horváth A, Kárpáti S. Successful treatment of lichen planus with adalimumab. Acta Derm Venereol. 2012;92(4):385–6.PubMedCrossRef

107.

Solimani F, Pollmann R, Schmidt T, Schmidt A, Zheng X, Savai R, et al. Therapeutic targeting of Th17/Tc17 cells leads to clinical improvement of lichen planus. Front Immunol. 2019;10:1808.PubMedPubMedCentralCrossRef

108.

AbuHilal M, Walsh S, Shear N. Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast. J Dermatol Case Rep. 2016;10(3):56–7.PubMedPubMedCentral

109.

Bettencourt M. Oral lichen planus treated with apremilast. J Drugs Dermatol. 2016;15(8):1026–8.PubMed

110.

Paul J, Foss CE, Hirano SA, Cunningham TD, Pariser DM. An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series. J Am Acad Dermatol. 2013;68(2):255–61.PubMedCrossRef

111.

Perschy L, Anzengruber F, Rappersberger K, Itzlinger-Monshi B, Aichelburg MC, Graf V, et al. Apremilast in oral lichen planus—a multicentric, retrospective study. J Dtsch Dermatol Ges. 2022;20(3):343–6.PubMed

112.

Shao S, Tsoi LC, Sarkar MK, Xing X, Xue K, Uppala R, et al. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med. 2019;11(511):eaav7561.PubMedPubMedCentralCrossRef

113.

Abduelmula A, Bagit A, Mufti A, Yeung KCY, Yeung J. The use of janus kinase inhibitors for lichen planus: an evidence-based review. J Cutan Med Surg. 2023;23:12034754231156100.

114.

Moussa A, Colla T, Morrison B, Sinclair R. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib. Australas J Dermatol. 2022;63(2):276–7.PubMedCrossRef

115.

Kooybaran NR, Petzold G, Ströbel P, Schön MP, Mössner R. Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib. J Dtsch Dermatol Ges. 2021;19(12):1778–80.PubMedCrossRef

116.

Balestri R, Bortolotti R, Rech G, Girardelli CR, Zorzi MG, Magnano M. Treatment of oral erosive lichen planus with upadacitinib. JAMA Dermatol. 2022;158(4):457–8.PubMedCrossRef

117.

Hoseinpour Jajarm H, Asadi R, Bardideh E, Shafaee H, Khazaei Y, Emadzadeh M. The effects of photodynamic and low-level laser therapy for treatment of oral lichen planus—a systematic review and meta-analysis. Photodiagnosis Photodyn Ther. 2018;23:254–60.PubMedCrossRef

118.

He Y, Deng J, Zhao Y, Tao H, Dan H, Xu H, et al. Efficacy evaluation of photodynamic therapy for oral lichen planus: a systematic review and meta-analysis. BMC Oral Health. 2020;20(1):302.PubMedPubMedCentralCrossRef

119.

Hanna R, Dalvi S, Tomov G, Hopper C, Rebaudi F, Rebaudi AL, et al. Emerging potential of phototherapy in management of symptomatic oral lichen planus: a systematic review of randomised controlled clinical trials. J Biophotonics. 2023;5: e202300046.CrossRef

120.

Gonzalez-Moles MA, Bravo M, Gonzalez-Ruiz L, Ramos P, Gil-Montoya JA. Outcomes of oral lichen planus and oral lichenoid lesions treated with topical corticosteroid. Oral Dis. 2018;24(4):573–9.PubMedCrossRef

121.

Mignogna MD, Lo Russo L, Fedele S. Gingival involvement of oral lichen planus in a series of 700 patients. J Clin Periodontol. 2005;32(10):1029–33.PubMedCrossRef

122.

Garcia-Pola MJ, Rodriguez-López S, Fernánz-Vigil A, Bagán L, Garcia-Martín JM. Oral hygiene instructions and professional control as part of the treatment of desquamative gingivitis. Systematic review. Med Oral Patol Oral Cirugia Bucal. 2019;24(2):e136–44.

123.

Stone SJ, McCracken GI, Heasman PA, Staines KS, Pennington M. Cost-effectiveness of personalized plaque control for managing the gingival manifestations of oral lichen planus: a randomized controlled study. J Clin Periodontol. 2013;40(9):859–67.PubMedCrossRef

Titel: Oral Lichen Planus: An Update on Diagnosis and Management
verfasst von: Agathe Louisy
Eiryann Humbert
Mahtab Samimi
Publikationsdatum: 15.09.2023
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 1/2024
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-023-00814-3

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments

Non-invasive Skin Imaging in Cutaneous Lymphomas

Treat-to-Target in Atopic Dermatitis

Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study